Drug
Mgd013 Monotherapy
Mgd013 Monotherapy: highest development phase Phase 1/2, developed by Zai Lab. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Zai Lab
Trials
| Drug | Phase | Indication |
|---|---|---|
| MGD013 monotherapy NCT04212221 | Phase 1/2 | Advanced Hepatocellular Carcinoma (HCC) |
Latest
No recent events.
Follow Mgd013 Monotherapy on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.